Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Molnupiravir  COVID-19 treatment studies for Molnupiravir  C19 studies: Molnupiravir  Molnupiravir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Combined death/ventilat.. -12% Improvement Relative Risk Hospitalization -17% c19early.org/m Yip et al. Molnupiravir for COVID-19 EARLY TREATMENT Is early treatment with molnupiravir beneficial for COVID-19? Retrospective 88,962 patients in China (February - March 2022) Higher hospitalization with molnupiravir (not stat. sig., p=0.062) Yip et al., Clinical Infectious Diseases, doi:10.1093/cid/ciac687 Favors molnupiravir Favors control
Impact of the use of oral antiviral agents on the risk of hospitalization in community COVID-19 patients
Yip et al., Clinical Infectious Diseases, doi:10.1093/cid/ciac687 (date from earlier preprint)
Yip et al., Impact of the use of oral antiviral agents on the risk of hospitalization in community COVID-19 patients, Clinical Infectious Diseases, doi:10.1093/cid/ciac687 (date from earlier preprint)
May 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Propensity score weighted retrospective of 93,883 outpatients in Hong Kong, 5,808 treated with molnupiravir and 4,921 treated with paxlovid, showing higher hospitalization and higher combined mortality/mechanical ventilation/ICU admission with molnupiravir, without statistical significance; and lower hospitalization and combined mortality/mechanical ventilation/ICU admission with paxlovid, statistically significant only for hospitalization.
Concerns have been raised that the mutagenic mechanism of action may create dangerous variants or cause cancer [Hadj Hassine, Swanstrom]. See [Fountain-Jones, Sanderson, twitter.com] for analysis of variants potentially created by molnupiravir.
combined death/ventilation/ICU, 12.0% higher, HR 1.12, p = 0.66, treatment 53 of 5,808 (0.9%), control 151 of 83,154 (0.2%), propensity score weighting, Cox proportional hazards, day 30.
risk of hospitalization, 17.0% higher, HR 1.17, p = 0.06, treatment 437 of 5,808 (7.5%), control 1,322 of 83,154 (1.6%), propensity score weighting, Cox proportional hazards, day 30.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Yip et al., 24 May 2022, retrospective, placebo-controlled, China, peer-reviewed, 11 authors, study period 16 February, 2022 - 31 March, 2022.
Contact: wonglaihung@cuhk.edu.hk.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperMolnupiravirAll
Abstract: Page 1 of 21 COVID-19 oral antivirals and hospitalisation Yip, et al. iew ed Impact of the use of oral antiviral agents on the risk of hospitalisation in community COVID-19 patients Running title: COVID-19 oral antivirals and hospitalisation risk in community Terry Cheuk-Fung Yip*1,2,3, Grace Chung-Yan Lui*1,2,4, Mandy Sze-Man Lai1,2, Vincent WaiSun Wong 1,2,3, Yee-Kit Tse1,2,3, Bosco Hon-Ming Ma1, Elsie Hui1, Maria KW Leung6, Henry ev Lik-Yuen Chan2,5,7, David Shu-Cheong Hui1,2,4, Grace Lai-Hung Wong1,2,3 1Department of Medicine and Therapeutics, 2Medical Data Analytics Centre (MDAC), 3Institute er r of Digestive Disease, 4Stanley Ho Centre for Emerging Infectious Diseases, Jockey Club School of Public Health & Primary Care, and Faculty of Medicine5, The Chinese University of Hong Kong; Hong Kong pe 6Department of Family Medicine, Prince of Wales Hospital, Hospital Authority, Hong Kong 7Department of Internal Medicine, Union Hospital, Hong Kong *TCF Yip and GCY Lui contributed equally to this study. ot Keywords: SARS-CoV-2, hospital admission, death, molnupiravir, nirmatrelvir/ritonavir Abbreviations: CDARS = Clinical Data Analysis and Reporting System, CI = confidence tn interval, DM = diabetes mellitus, ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification, IMV = invasive mechanical ventilation, HR = hazard ratio, ICU rin = intensive care unit, SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2. 300 Text word count: 3,441 No. of tables: 3 No. of figures: 2 ep Summary word count: Co-correspondence: Pr 1. Grace Lai-Hung Wong, MBChB(Hons, CUHK), MD(CUHK), FRCP(Lond, Edin), FHKCP, FHKAM(Medicine) 1 This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=4112160 Page 2 of 21 COVID-19 oral antivirals and hospitalisation Yip, et al. iew ed 2. David Shu-Cheong Hui, MBBS (UNSW); MD(UNSW); FRACP; FRCP (Lond, Glasg, Edin); FHKCP; FHKAM(Medicine) Department of Medicine and Therapeutics, 9/F Prince of Wales Hospital, Shatin, Hong Kong. Telephone: 852-2632-3538, Fax:852-2637-3852, Email: wonglaihung@cuhk.edu.hk Declaration of Interests ev Terry Yip has served as an advisory committee member and a speaker for Gilead Sciences. Grace Lui has served as an advisory committee member for Gilead, Merck and GSK, speaker for er r Merck and Gilead, and received research grant from Gilead, Merck and GSK. Vincent Wong has served as a consultant or advisory committee member for AbbVie, Boehringer Ingelheim, Echosens, Gilead Sciences, Intercept, Inventiva, Merck, Novo Nordisk, pe Pfizer, ProSciento, Sagimet Biosciences and TARGET PharmaSolutions; and a speaker for Abbott, AbbVie, Echosens, Gilead Sciences and Novo Nordisk. He has received a research grant from Gilead Sciences, and is a cofounder of Illuminatio Medical Technology Limited. ot Henry Chan has served as an Independent Non-Executive Director for Shanghai Henlius Biotech Inc; as an advisory board member for Aligos, Aptorum, Arbutus, Hepion, Janssen, Gilead, tn Glaxo-Smith-Kline, Roche, Vaccitech, Virion Therapeutics, and Vir Biotechnology; and as a speaker for Gilead, Roche, and Viatris. rin Grace Wong has served as an advisory committee member for Gilead Sciences and Janssen, and as a speaker for Abbott, Abbvie, Ascletis, Bristol-Myers Squibb, Echosens, Gilead Sciences, ep Janssen and Roche. She has also received a research grant from Gilead..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit